Ameliorative effect of Phoenix dactylifera on adverse effects of Linezolid in rats | ||||
| Zagazig Veterinary Journal | ||||
| Article 26, Volume 45, Supplementary 1, October 2017, Page 257-266 PDF (261.23 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zvjz.2017.29245 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Elsayed A. Abdel Aziz; Sameh M. El-Nabtity; Mahmoud A.A. Said 
| ||||
| Pharmacology Department, Faculty of Veterinary Medicine, Zagazig University, 44511, Egypt | ||||
| Abstract | ||||
| Linezolid is one of the oxazolidinone antibiotics that is used to treat methicillin resistant staphylococcus aureus (MRSA) & vancomycin resistant Staphylococcus aureus. This study aimed to investigate the adverse effects of linezolid on bone marrow and, kidneys and their counteraction by using Phoenix dactylifera methanolic extract in rats. It was found that oral administration of linezolid (100 mg/kg body weight) for 14 successive days induced a significant decrease in hemoglobin content (7.88±0.18 g/L) on the first day post-treatment, significant increase in serum urea (59.75±0.85) and creatinine (1.89±0.04) on the 14th day post- treatment. The concurrent oral administration of Phoenix dactylifera methanolic extract (1000 mg/kg body weight) and linezolid (100 mg/kg body weight) for the same period corrected the damaging effects of linezolid of the hemoglobin content, urea, creatinine of treated rats. It was concluded that methanolic extract of phoenix dactylifera clearly ameliorated these damaging effects of linezolid. | ||||
| Keywords | ||||
| Phoenix dactylifera; Linezolid; urea; creatinine; brain and bone marrow | ||||
|
Statistics Article View: 158 PDF Download: 200 |
||||
